HUTCHMED (NASDAQ:HCM) Shares Gap Up to $19.15

HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $19.15, but opened at $19.87. HUTCHMED shares last traded at $19.79, with a volume of 52,348 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have commented on HCM shares. StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Wednesday, March 27th. Cantor Fitzgerald restated an "overweight" rating on shares of HUTCHMED in a research note on Friday, January 12th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, HUTCHMED has a consensus rating of "Moderate Buy" and a consensus price target of $29.70.

HUTCHMED Trading Up 3.5 %

The company has a debt-to-equity ratio of 0.06, a current ratio of 2.72 and a quick ratio of 2.60. The company has a fifty day moving average price of $16.98 and a 200-day moving average price of $16.85.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of HUTCHMED by 353.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company's stock valued at $65,000 after buying an additional 2,801 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in HUTCHMED in the third quarter worth $196,000. Hsbc Holdings PLC bought a new stake in shares of HUTCHMED during the third quarter worth $380,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of HUTCHMED during the third quarter valued at $444,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of HUTCHMED by 54.9% in the first quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company's stock worth $721,000 after purchasing an additional 15,221 shares during the last quarter. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.